Free Trial
NASDAQ:IMAB

I-Mab (IMAB) Stock Price, News & Analysis

I-Mab logo
$0.82 -0.03 (-3.13%)
As of 02:12 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About I-Mab Stock (NASDAQ:IMAB)

Key Stats

Today's Range
$0.78
$0.83
50-Day Range
$0.80
$1.09
52-Week Range
$0.76
$2.00
Volume
128,000 shs
Average Volume
306,023 shs
Market Capitalization
$66.42 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$7.00
Consensus Rating
Buy

Company Overview

I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics in the fields of immuno-oncology and immuno-inflammation diseases primarily in the United States. It is developing Uliledlimab, a CD73 neutralizing antibody, which is in Phase 2 clinical trial for the treatment of solid tumors; Givastomig, a bi-specific antibody that is in Phase 1 clinical trial for the treatment of gastric and other cancers; and Ragistomig, a programmed cell death ligand-based tumor-dependent T cell engager, which is in Phase 1 clinical trial for the treatment of for solid tumors. The company is also evaluating opportunities to develop Lemzoparlimab, a fully human CD47 monoclonal antibody for cancer immunotherapy. It has strategic licensing agreement with Ferring International Center SA to research, develop, make, have made, import, use, sell and offer to sell FE301, an interleukin-6 inhibitor. The company has clinical collaboration with Bristol Myers Squibb to evaluate Claudin 18.2 x 4-1BB bispecific antibody givastomig in combination with nivolumab and chemotherapy for the treatment of gastric and esophageal cancer. I-Mab was founded in 2014 and is headquartered in Rockville, Maryland.

Remove Ads

I-Mab Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
54th Percentile Overall Score

IMAB MarketRank™: 

I-Mab scored higher than 54% of companies evaluated by MarketBeat, and ranked 500th out of 935 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    I-Mab has received a consensus rating of Buy. The company's average rating score is 3.33, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    I-Mab has only been the subject of 1 research reports in the past 90 days.

  • Read more about I-Mab's stock forecast and price target.
  • Earnings Growth

    Earnings for I-Mab are expected to decrease in the coming year, from ($0.56) to ($1.35) per share.

  • Price to Book Value per Share Ratio

    I-Mab has a P/B Ratio of 0.28. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about I-Mab's valuation and earnings.
  • Percentage of Shares Shorted

    1.48% of the float of I-Mab has been sold short.
  • Short Interest Ratio / Days to Cover

    I-Mab has a short interest ratio ("days to cover") of 2.4, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in I-Mab has recently increased by 5.97%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    I-Mab does not currently pay a dividend.

  • Dividend Growth

    I-Mab does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    1.48% of the float of I-Mab has been sold short.
  • Short Interest Ratio / Days to Cover

    I-Mab has a short interest ratio ("days to cover") of 2.4, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in I-Mab has recently increased by 5.97%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    I-Mab has a news sentiment score of 0.62. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.82 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 3 news articles for I-Mab this week, compared to 1 article on an average week.
  • Search Interest

    Only 1 people have searched for IMAB on MarketBeat in the last 30 days. This is a decrease of -75% compared to the previous 30 days.
  • MarketBeat Follows

    2 people have added I-Mab to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, I-Mab insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    22.10% of the stock of I-Mab is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Only 38.38% of the stock of I-Mab is held by institutions.

  • Read more about I-Mab's insider trading history.
Receive IMAB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for I-Mab and its competitors with MarketBeat's FREE daily newsletter.

IMAB Stock News Headlines

I-Mab to Present at 24th Annual Needham Virtual Healthcare Conference
I-Mab faces Nasdaq delisting over bid price rule
The Same Setup That Led to a 131% Gold Surge Is Happening Now
Historically, when confidence in credit markets gets too high, a gold acceleration phase follows… And we’re seeing the same setup playing out again… With central banks piling into gold, inflation lingering, and debt levels soaring, I believe we’re on the verge of another Gold acceleration cycle—and it could happen fast. Back in November, I told folks to “buy the dip” in gold and I sure hope they listened… I cannot promise future returns or against losses, but now I’m giving you another heads-up… I broke down exactly what I am seeing and how anyone with a regular brokerage account can take advantage… Without actually holding any gold…
I-Mab receives Nasdaq deficiency notice
See More Headlines

IMAB Stock Analysis - Frequently Asked Questions

I-Mab's stock was trading at $0.85 at the beginning of the year. Since then, IMAB shares have decreased by 3.4% and is now trading at $0.8210.
View the best growth stocks for 2025 here
.

I-Mab (IMAB) raised $100 million in an initial public offering (IPO) on Thursday, January 16th 2020. The company issued 7,400,000 shares at a price of $12.00-$15.00 per share. Jefferies and CICC acted as the underwriters for the IPO and China Renaissance and Huatai Securities (USA) were co-managers.

I-Mab's top institutional investors include Hhlr Advisors LTD. (7.34%), Two Sigma Advisers LP (0.53%), Two Sigma Investments LP (0.41%) and Cantor Fitzgerald L. P. (0.17%).

Shares of IMAB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that I-Mab investors own include NVIDIA (NVDA), Tesla (TSLA), CrowdStrike (CRWD), NIO (NIO), Plug Power (PLUG), HubSpot (HUBS) and Intel (INTC).

Company Calendar

Today
3/31/2025
Next Earnings (Estimated)
4/03/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:IMAB
Fax
N/A
Employees
380
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$7.00
High Stock Price Target
$8.00
Low Stock Price Target
$6.00
Potential Upside/Downside
+732.0%
Consensus Rating
Buy
Rating Score (0-4)
3.33
Research Coverage
3 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$3.27 million
Price / Cash Flow
N/A
Book Value
$2.93 per share
Price / Book
0.29

Miscellaneous

Free Float
63,489,000
Market Cap
$68.57 million
Optionable
Optionable
Beta
1.15
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

This page (NASDAQ:IMAB) was last updated on 3/31/2025 by MarketBeat.com Staff
From Our Partners